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Specific Care Question
In pediatric patients with brain tumors, does the use of dexamethasone as an antiemetic versus not using dexamethasone result in decreased overall
survival or tumor recurrence?
Recommendations Based on Current Literature (Best Evidence) Only
A conditional recommendation is made against the routine use of dexamethasone as an antiemetic in patients with brain tumors, based on review of
current literature by the Department of EBP. Consideration could be given to dexamethasone use as an antiemetic in cases of severe refractory
chemotherapy-induced nausea/vomiting after other agents have proven ineffective. The overall certainty in the evidence is very low. Due to the lack of
evidence for safety concerns of dexamethasone in the treatment of nausea and vomiting in pediatric patients with brain tumors, this review included
studies that used dexamethasone for the treatment of cerebral edema in adult and pediatric patients with brain tumors. Three of the four included
studies found a significant associated decrease in overall survival rates of patients treated with dexamethasone. This concurs with the Multinational
Association of Supportive Care in Cancer (MASCC), which recommends against the use of dexamethasone in children receiving radiation and
chemotherapy treatment of brain tumors.
Literature Summary
Background. Dexamethasone has been shown to be an effective treatment for nausea and vomiting in patients with cancer (Phillips et al., 2016).
While adding dexamethasone improves control of vomiting, clinical studies have not found an association with steroids as an antiemetic and poor
outcome (Phillips et al., 2016). Current antiemetic practice guidelines from the American Society of Clinical Oncology (ASCO) (Hesketh et al., 2017)
recommend the use of a 5HT3 receptor antagonist, dexamethasone, plus aprepitant for children receiving highly emetogenic chemotherapy (HEC). The
guideline makes no mention of treatment for pediatric patients with brain tumor. It does recommend adult patients who are treated with radiation
therapy to the brain should be offered rescue dexamethasone therapy. The use of dexamethasone is not without its concerns in patients with brain
tumors. This is due to the concern for potential impairment of the blood–brain permeability, concerns regarding potential interference with apoptosis,
and fungal infection (Dupuis, Roscoe, Olver, Aapro, & Molassiotis, 2017). A guideline by MASCC recommends against or strongly discourages the use
of dexamethasone in children receiving radiation and chemotherapy treatment of brain tumors (Dupuis et al., 2017).
Dexamethasone is also commonly used in patients with brain tumors to reduce cerebral edema (Hui, Rudra, Ma, Campian, & Huang, 2019). However,
the use of dexamethasone for the treatment of cerebral edema has come under scrutiny, due to the same side-effects when used as an antiemetic
(Wong, Lok, Gautam, & Swanson, 2015). Due to the paucity of evidence in the efficacy of dexamethasone in the treatment of nausea and vomiting in
pediatric patients with brain tumors, this review included studies that reviewed dexamethasone for the treatment of cerebral edema in patients with
brain tumors. This review will summarize current literature on the topic.
Study characteristics. The search for suitable studies was completed on November 23, 2019. J. Thompson, MD reviewed the 99 titles and/or
abstracts in December 2019 and March 2020 and identified two guidelines and twenty single studies believed to answer the question.a J. Thompson,
MD reviewed the articles twice to assure appropriate literature was selected for this topic. After an in-depth review of the guidelinesd and single
studiesb, two guidelines (Dupuis et al., 2017; Hesketh et al., 2017) and four cohort studies (Dubinski et al., 2018; Hui et al., 2019; Shields et al.,
2015; Wolff, Hauch, Kuhl, Egeler, & Jurgens, 1998) answered the question and are included in this review (see Figure 1).
The AGREE IId tool was used to assess the guidelines. Both guidelines were selected with the recommendation to be used without modification (Dupuis
et al., 2017; Hesketh et al., 2017) (see Table 1).
Summary by outcome
Overall survival. Four cohort studies (Dubinski et al., 2018; Hui et al., 2019; Shields et al., 2015; Wolff et al., 1998) measured overall survival (OS),
(N = 401). A meta-analysis was not completed due to the heterogeneity of the included studies. In a study of children with brain tumors (n = 20)
methotrexate with dexamethasone versus methotrexate without dexamethasone was compared (Wolff et al., 1998). There were no therapy related
deaths in either group during chemotherapy. Dubinski et al. (2018) reviewed the effects of dexamethasone-induced leukocytosis on OS in adults (n =
59) with newly diagnosed glioblastoma (GBM). The study reported the presence of dexamethasone-induced leukocytosis decreased OS, Hazard ratio
(HR) = 2.25, 95% CI [1.15, 4.38], p < .001. Hui et al. (2019) compared high versus low corticosteroid exposure during chemotherapy on adults (n =
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319) with newly diagnosed GBM. High-dose corticosteroid cohort was independently associated with decreased OS, HR = 1.131, 95% CIs [1.059,
1.208]. Shields et al. (2015) reviewed the effects of dexamethasone on OS adults with newly diagnosed GBM (n = 73). Patients weaned off
dexamethasone had an OS of 22.5 months compared to 12.7 months for those not weaned off dexamethasone, p = .02.
Certainty of the evidence for overall survival. The certainty of the body of evidence was very low based on four factors c: within-study risk of
bias, consistency among studies, directness of evidence, and precision of effect estimates. The body of evidence was assessed to have serious risk
of bias, serious inconsistency and very serious indirectness. Risk of bias was serious due to the studies were all retrospective cohorts. The
consistency was serious due to the heterogeneity of the study designs. Indirectness was very serious due to three of the four studies included
adults (Dubinski et al., 2018; Hui et al., 2019; Shields et al., 2015) and none of the studies used corticosteroids as an antiemetic.
Identification of Studies which database?
Search Strategy and Results (see Figure 1)
Pubmed
("brain tumor*"[tiab] OR "Brain Neoplasms"[Mesh]) AND "Dexamethasone/adverse effects"[Mesh] NOT "Case Reports" [Publication Type]
("brain tumor*" OR "Brain Neoplasms"[Mesh]) AND ("Antineoplastic Agents"[Mesh] OR "Nausea/chemically induced"[MeSH] OR "Vomiting/chemically
induced"[MeSH]) AND ("Antiemetics"[Mesh] OR ("Dexamethasone"[Mesh] AND ("antiemetics"[Mesh] OR "Vomiting/prevention and control"[Mesh] OR
"Nausea/prevention and control"[Mesh])))
"Antineoplastic Agents/adverse effects"[Majr] ) AND ("Antiemetics/therapeutic use"[Majr] OR ("Dexamethasone/therapeutic use"[Majr] AND
("antiemetics"[Majr] OR "Vomiting/prevention and control"[Mesh] OR "Nausea/prevention and control"[Mesh]))) AND (child OR children OR pediatr* OR
paediatr* OR childhood)
Records identified through database searching n = 99
Studies Included in this Review
Citation
Study Type
Dubinski et al. (2018)
Cohort
Dupuis et al. (2017)
Guideline
Hesketh et al. (2017)
Guideline
Hui et al. (2019)
Cohort
Shields et al. (2015)
Cohort
Wolff et al. (1998)
Cohort
Studies Not Included in this Review with Exclusion Rationale
Citation
Basch et al. (2011)
Duggin et al. (2014)
Dupuis et al. (2013)
Hempen, Weiss, and Hess (2002)
Ikeda, Carson, Lauer, and Long (1993)
Kostopoulou et al. (2018)
Matsuda et al. (2016)
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Nahaczewski, Fowler, and Hariharan (2004)
Nestler, Winking, and Boker (2002)
Patel, Paw Cho Sing, and Dupuis (2019)
Phillips et al. (2016)
Pitter et al. (2016)
Schulte (1983)
Takeuchi et al. (2016)
Waxman, Beldon, Richli, Tanasescu, and Siemsen (1978)

Review article
Non-human
Outcome of interest not reported
Outcome of interest not reported
Non-human
Non-English
Does not discuss brain tumor patients
Outcome of interest not reported

Methods Used for Appraisal and Synthesis
aRayyan is a web-based software used for the initial screening of titles and / or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid,
2017).
bReview Manager (Higgins & Green, 2011) is a Cochrane Collaborative computer program used to assess the study characteristics as well as the risk of bias
and create the forest plots found in this analysis.
cThe GRADEpro Guideline Development Tool (GDT) is the tool used to create the Summary of Findings table(s) for this analysis.
dThe Appraisal of Guidelines Research and Evaluation II (AGREE II) is an international instrument used to assess the quality and reporting of clinical practice
guidelines for this analysis (Brouwers et al. 2010).
eThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched,
screened, and eligibility criteria is applied (Moher, Liberati, Tetzlaff, & Altman, 2009).
aOuzzani,

M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. Systematic Reviews, 5(1),
210. doi:10.1186/s13643-016-0384-4
bHiggins, J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cochrane Collaboration, 2011.
cGRADEpro GDT: GRADEpro Guideline Development Tool (2015). McMaster University, (developed by Evidence Prime, Inc.). [Software]. Available
from gradepro.org.
dBrouwers, M.C. et al. for the AGREE Next Steps Consortium. (2010) AGREE II: Advancing guideline development, reporting and evaluation in
healthcare. Canadian Medical Association Journal, 182, E839-842. Retrieved from https://www.agreetrust.org/wp-content/uploads/2017/12/AGREEII-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf
eMoher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.
Question Originator
J. Thompson, MD
Medical Librarian Responsible for the Search Strategy
K. Swaggart, MLIS, AHIP
EBP Team or EBP Scholar’s Responsible for Analyzing the Literature
N. H. Allen, MS, MLS, RD, LD, CPHQ
J. A. Bartlett, PhD, RN
T. Bontrager, MSN, RN, CPEN
J. Edwards, RN, MSN, CPEN
D. Kemper, BHS, RRT, RRT-NPS, C-NPT
L. Martin, RN, BSN, CPAN
R. McCracken, RRT, NPS
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H. Murphy, BHS RRT AE-C
A. Randall, MHA, RRT, RRT-ACCS, RRT-NPS, C-NPT, CPPS
K. Robertson, MBA, MT-BC
J. Wierson, RN, BSN, MBA, CCRC
A. Wilson, BSN, RN, CPN
EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document
J. Dusin, MS, RD, LD, CPHQ
Acronyms Used in this Document
Acronym
Explanation
AGREE II
Appraisal of Guidelines Research and Evaluation II
ASCO
American Society of Clinical Oncology
ASL
Acute severe lymphopenia
BEZ
Bevacizumab
CAT
Critically Appraised Topic
DEX
Dexamethasone
EBP
Evidence Based Practice
GBM
Glioblastoma
GTR
Gross-total resection
HEC
Highly emetogenic chemotherapy
MASCC
Multinational Association of Supportive Care in Cancer
MXT
Methotrexate
OS
Overall Survival
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PFS
Progression-free survival
TMZ
Temozolomide
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)e
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Table 1
AGREE IId Summary for the ASCO Guideline (Hesketh et al., 2017)
Domain

Percent Agreement

Scope and purpose

97%

Stakeholder involvement

81%

Rigor of development

90%

Clarity and presentation

92%

Applicability

58%

Editorial independence

83%

Overall guideline assessment
Team’s recommendation for guideline use

6
Yes

Note: Four EBP Team members or Scholars completed the AGREE II on this guideline.
Table 2
AGREE IId Summary for the MASCC Guideline (Dupuis et al., 2017)
Domain

Percent Agreement

Scope and purpose

93%

Stakeholder involvement

51%

Rigor of development

69%

Clarity and presentation

61%

Applicability

19%

Editorial independence

94%

Overall guideline assessment
Team’s recommendation for guideline use

5
Yes

Note: Four EBP Team members or Scholars completed the AGREE II on this guideline.
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Characteristics of Intervention Studies
Dubinski et al. (2018)
Characteristics of Study
Methods
Retrospective Cohort
Participants
Participants: Adults with newly diagnosed GBM
Setting: University Hospital in Helsinki
Number enrolled into study: N = 113
Gender, males: (as defined by researchers)
• n = 59 (52%)
Race / ethnicity or nationality (as defined by researchers):
• The study occurred in Helsinki, Finland. The authors did not identify race or
ethnicity of the participants.
Age, years, standard deviation
• 58 (12.72)
Inclusion criteria:
• Patients admitted to the hospital who were newly diagnosed with GBM
• Underwent craniotomy from 2011 to 2013
Exclusion criteria:
• Patients with pre-existing disease likely to impact their immune status
(bacterial infection, fewer, congenital or acquired immunodeficiency,
autoimmune disease, or current immunotherapy)
• Patients detailed DEX intake was not reported.
Covariates identified:
• Not reported
Interventions
• Symptomatic patients whose condition was attributed to peritumoral edema
received 12 mg DEX per day.
• DEX was administrated until craniotomy, which was performed within 4 ± 1
day after admission.
• All patients received 40 mg DEX during the perioperative period to reduce
surgically induced cerebral edema.
Outcomes
Primary outcome(s):
• To correlate the initial DEX response with patient’s survival and
to analyze its effect on tumor leukocyte infiltration in newly diagnosed
glioblastoma (GBM) patients.
• Disease progression was diagnosed in case of either new gadolinium
enhancement, T2 FLAIR progression, worsening of neurologic symptoms or
death.
OS was defined as the time interval between diagnosis and death.
Results
Results:
• Patient age was identified to be a risk factor for the development of
dexamethasone- induced leukocytosis, median = 63 years, p < .05.
• The presence of dexamethasone-induced leukocytosis decreased overall
survival, HR = 2.25, 95% CI [1.15, 4.38]; p < .001.
• The presence of dexamethasone-induced leukocytosis
decreased progression-free survival, HR = 2.23, 95% CI [1.09, 4.59]; p <
.01.
Limitations:
• Analysis was retrospective
• Several patients were excluded due to the lack of detailed DEX intake data,
making a selection bias possible.
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Hui et al. (2019)
Characteristics of Study
Methods
Participants

Interventions

Retrospective cohort
Participants: Adults newly diagnosed with nonmetastatic GBM who received
standard photon radiotherapy with concurrent chemotherapy
Setting: Washington University Medical Center, St. Louis, MO
Number enrolled into study: N = 319
• Group 1, Low-dose corticosteroid (< 2 mg/day): n = 170
• Group 2, High-dose corticosteroid (>2 mg/day): n = 149
Number completed: N = 319
Gender, males: (as defined by researchers)
• Group 1: n = 106 (62%)
• Group 2: n = 88 (59%)
Race / ethnicity or nationality (as defined by researchers):
• Group 1:
• White: n = 159 (94%)
• Other: n = 11 (6%)
• Group 2:
• White: n = 140 (94%)
• Other: n = 9 (6%)
Age, median in years (range)
• Group 1: 57 (22-82)
• Group 2: 57 (21-78)
Inclusion criteria:
• Patients newly diagnosed with nonmetastatic GBM
• Patients that:
o Received standard photon radiotherapy with concurrent
chemotherapy
o Had an absolute lymphocyte count drawn at baseline (prior to
radiation therapy) and within 3 months after starting radiation therapy
o Corticosteroid use at baseline and during chemoradiotherapy
Exclusion criteria:
• Patients treated with proton radiation therapy for resected GBM < 5 cm
Covariates identified:
• Gross-total resection (GTR)
Both:

•

Outcomes

Radiation therapy was delivered by either:
o 3D conformal technique
o Intensity modulated photon-based technique
• A cumulative dexamethasone dose was calculated by recording the dose
recorded at four timepoints:
o Baseline (within two weeks of radiation therapy)
o Week 2 (+ 1 week)
o Week 4 (+ 1 week)
o Week 6 (+ 1 week)
Primary outcomes:
• Acute severe lymphopenia (ASL) defined as occurrence of ALC < 500
cells/mL within three months of starting RT
• Overall survival (OS)*
• Progression-free survival (PFS)
Secondary outcomes:
• Subgroup analysis of GTR group
*Outcomes of interest to the CMH CPG or CAT development team
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Results

Univariate analysis:
• ASL
High-dose corticosteroid cohort had significantly higher ASL rates
(43.7%) compared to the low-dose cohort (19.8%) rates (p < .001)
• OS (median follow up time of 14.6 months)
High-dose corticosteroid cohort had significantly worse OS rates (12.6
months) compared to the low-dose cohort (17.9 months), p < .001
• PFS
High-dose corticosteroid cohort (7.1 months) not
significantly different compared to the low-dose cohort (8.1
months), p = .163
Multivariate analysis:
• ASL
o High-dose corticosteroid was independently associated with ASL OR =
1.283, 95% CIs [1.143, 1.441]
o Average corticosteroid use was not significantly associated with ASL
o GTR subgroup analysis: Higher average corticosteroids were
not independently associated with ASL OR = 1.804, 95% CIs [1.345,
2.420]
• OS
o High-dose corticosteroid cohort was independently associated
with OS HR = 1.131 95% CIs [1.059, 1.208]
o Average corticosteroid use was not reported
o Higher average corticosteroid was not independently associated
with OS
• PFS
o High-dose corticosteroid cohort (7.1 months) not significant
o Average corticosteroid use was not significantly associated with PFS
o Higher average corticosteroid was not independently associated with
PFS
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Shields et al. (2015)
Characteristics of Study
Methods
Participants

Interventions

Retrospective cohort
Participants: Adults with GBM
Setting: The Norton Cancer Institute, Louisville KY, USA
Number enrolled into study: N = 73
Primary analysis- (did not answer the question asked and therefore those
study findings are not included in this report)
Secondary analysis
• Secondary Group 1: Able to stop dexamethasone during radiation
therapy: n = 36
• Secondary Group 2: Unable to stop dexamethasone during radiation
therapy: n = 37
Number completed: N = 73
Gender, males: (as defined by researchers)
• Primary analysis: 44 (60%)
• Secondary analysis: Not reported
Race / ethnicity or nationality (as defined by researchers):
• The study occurred in Kentucky, USA. The authors did not identify race or
ethnicity of the participants.
Age, median in years
• 61
Inclusion criteria:
• Diagnosed with GBM multiforme
• Treated with 30 fractions of simultaneous integrated boost radiation
therapy, concurrent with BEV and TMZ, combined or TMZ alone
Exclusion criteria:
• None reported
Covariates identified:
• The cohort spans a time frame when the RTOG 0825 and AVAGlio studies
were reported
o Subjects prior to the reporting of the above studies received both
BEV and TMZ
o Subjects after the reporting of the above studies received BEV only.
Both:
• All subjects underwent surgical resection of the GBM, and extent of
resection was determined by MRI.
• All subjects received radiation therapy, of 30 identical fractions delivered
once daily five times per week, for 6 weeks.
• All subjects received DEX after surgical resection to manage intracranial
edema, and to control neurological symptoms. The goal was to wean DEX
prior to starting radiation therapy. Dose not reported.
Group 1:
•
Subjects received TMZ (75 mg/m2) daily, and BEV (10 mg/kg) every two
weeks during 6 weeks of radiation therapy. One month after radiation
therapy, TMZ (150 mg/m2 for 5 days, monthly and BEV 10 mg/kg every
two weeks until progression, toxicities, or 12 months total.
Group 2:
•
Subjects received TMZ (75 mg/m2) daily during 6 weeks of radiation
therapy. One month after radiation therapy TMZ (150 mg/m2 for 5 days,
monthly for up to one year. If salvage therapy was needed, subjects were
offered BEV infusion every three weeks (n = 19 in this group who
required salvage therapy)
Secondary analysis:
• Group 1: Patients who weaned from DEX prior to radiation therapy
• Group 2: Patients who continued to receive DEX during radiation therapy
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Outcomes

Results

Primary outcomes of secondary analysis:
• *Progression free time (PFS)- interval between diagnosis and
progression
• *Overall survival time (OS)- interval between diagnosis and death from
any cause
Secondary outcome(s)
• Not reported
Safety outcome(s):
• Not reported
*Outcomes of interest to the CMH CPG or CAT development team
Results:
• Overall
• Progression free time, median
o DEX weaned – 8.8 months
o DEX not weaned - 6 months
o p = .002
• Overall survival, median
o DEX weaned – 22.5 months
o DEX not weaned - 12.7
o p = .02
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Wolff et al. (1998)
Characteristics of Study
Methods
Participants

Retrospective cohort
Participants: Children
Setting: Children’s Hospital, Canada
Number enrolled into study: N = 20, who underwent 57 courses of
chemotherapy
• Group 1, Courses with methotrexate alone (MTX): n = 24
• Group 2, Courses with MTX and DEX: n = 33
Number completed: N = 20, who underwent 57 courses
• Group 1, Courses with MTX alone: n = 24
• Group 2, Courses with MTX and DEX: n = 33
Gender, males: (as defined by researchers)
• Group 1: Subjects n =4/8 received MTX and DEX (50%)
• Group 2: Subjects n = 9/12 received MTX and DEX (75%)
Race / ethnicity or nationality (as defined by researchers):
The study occurred in Germany. The authors did not identify race or ethnicity
of the participants.
Age, years, mean (range)
• Group 1: received MTX alone, 4.6 (1 to 15)
• Group 2: received MTX and DEX. 4.6 (1 to 7)
Inclusion criteria:
• Brain tumor
• Treated with MTX or MTX with DEX
Exclusion criteria:
• None stated
Covariates identified: Not reported

•
•

Interventions
Outcomes

Results

Group 1: Treated with MTX alone
Group 2: Treated with MTX and DEX.

Primary outcome:
• *Survival
Secondary outcome
• *Disease progression
Safety outcome(s):
• Not reported
*Outcomes of interest to the CMH CPG or CAT development team
Results:
• There were no therapy related deaths in either group during
chemotherapy
• Disease progression is not reported
• Hepatotoxicity was worse in the DEX group. Only p values are
reported.
o GOT and GPT maximal values were higher in those who received
DEX, p < .001.
o GOT and GPT increases were higher in those who received
DEX, p < .01
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